ID   PEO6
AC   CVCL_2691
SY   PE06; PEO-6
DR   BTO; BTO:0005798
DR   EFO; EFO_0005449
DR   cancercelllines; CVCL_2691
DR   CancerTools; 151674
DR   Cell_Model_Passport; SIDM00470
DR   ECACC; 10032310
DR   GEO; GSM459855
DR   GEO; GSM659400
DR   GEO; GSM1340591
DR   GEO; GSM1341133
DR   GEO; GSM2475003
DR   Progenetix; CVCL_2691
DR   Wikidata; Q54947169
DR   Ximbio; 151674
RX   PubMed=3167863;
RX   PubMed=19654294;
RX   PubMed=20581869;
RX   PubMed=22183581;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=28273451;
RX   PubMed=30485824;
CC   Population: Caucasian.
CC   Doubling time: 77 hours (PubMed=3167863).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (PubMed=28273451).
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ECACC; PubMed=22183581; PubMed=22710073; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10
ST   D16S539: 9
ST   D18S51: 16
ST   D19S433: 13,15
ST   D21S11: 30 (PubMed=22710073)
ST   D21S11: 30,32.2 (PubMed=22183581; PubMed=30485824)
ST   D2S1338: 20,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 20
ST   TH01: 9.3
ST   TPOX: 9,11
ST   vWA: 15,16
DI   NCIt; C36101; BRCA2-associated hereditary breast and ovarian cancer syndrome
DI   NCIt; C5228; Ovarian cystadenocarcinoma
DI   ORDO; Orphanet_145; Hereditary breast and ovarian cancer syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2686 ! PEO1
OI   CVCL_2690 ! PEO4
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=3167863;
RA   Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A.,
RA   Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.;
RT   "Characterization and properties of nine human ovarian adenocarcinoma
RT   cell lines.";
RL   Cancer Res. 48:6166-6172(1988).
//
RX   PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178;
RA   Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J.,
RA   Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.;
RT   "Functional restoration of BRCA2 protein by secondary BRCA2 mutations
RT   in BRCA2-mutated ovarian carcinoma.";
RL   Cancer Res. 69:6381-6386(2009).
//
RX   PubMed=20581869; DOI=10.1038/onc.2010.245;
RA   Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J.,
RA   Langdon S.P., Huntsman D.G., Brenton J.D.;
RT   "Genomic analysis of genetic heterogeneity and evolution in high-grade
RT   serous ovarian carcinoma.";
RL   Oncogene 29:4905-4913(2010).
//
RX   PubMed=22183581; DOI=10.1002/path.3980;
RA   Ng C.K.Y., Cooke S.L., Howe K.L., Newman S., Xian J., Temple J.,
RA   Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.;
RT   "The role of tandem duplicator phenotype in tumour evolution in
RT   high-grade serous ovarian cancer.";
RL   J. Pathol. 226:703-712(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//